In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

Discover how psoriasis affects immune function and the role of SSAT1 in this chronic skin condition. Learn more now.

Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...